Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported total revenues of $2.3 billion for the fourth quarter of 2022. This compares to $2 billion in the same period a year ago. GAAP net income rose 6% year-over-year to $819 million, or $3.15 per share. Adjusted EPS increased 25% to $3.76. For full-year 2023, CF product revenues are expected […]
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported total revenues of $2.3 billion for the fourth quarter of 2022. This compares to $2 billion in the same period a year ago. GAAP net income rose 6% year-over-year to $819 million, or $3.15 per share. Adjusted EPS increased 25% to $3.76. For full-year 2023, CF product revenues are expected […]
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported total revenues of $2.3 billion for the fourth quarter of 2022. This compares to $2 billion in the same period a year ago.
GAAP net income rose 6% year-over-year to $819 million, or $3.15 per share. Adjusted EPS increased 25% to $3.76.
For full-year 2023, CF product revenues are expected to be $9.55-9.70 billion.
